At the recent Healthcare Information and Management Systems Society (HIMSS) annual conference, AT&T’s healthcare team demonstrated the key role connectivity and the internet of medical things (IoMT) plays throughout the continuum of care. This concept was highlighted by a demonstration of the Bodyport remote monitoring solution.

February 20, 2019 — Post-traumatic stress disorder (PTSD) by itself does not explain the increased risk of ...

Ochsner Health System in Louisiana recently announced a new partnership with device data management and remote monitoring vendor Geneva Health Solutions (GHS) for implantable cardiac devices. This partnership marks the first time the GHS cloud-based technology platform and remote monitoring service for patients with cardiac implants will be utilized in the region, which includes Louisiana, Arkansas, Mississippi, Alabama and Georgia. The GHS system will drive full automated scheduling and reporting in collaboration with Ochsner’s established Epic electronic medical record (EMR).

Patients receiving hormone therapy as part of their gender-transition treatment had an elevated risk for cardiovascular events, including strokes, heart attacks and blood clots, according to a study published in the American Heart Association’s journal Circulation.

IBM Watson Health and the Broad Institute of MIT and Harvard are launching a research partnership aimed at developing powerful predictive models that will enable clinicians to identify patients at serious risk for cardiovascular disease. This three-year project will incorporate population- and hospital-based biobank data, genomic information, and electronic health records to build upon and expand the predictive power of polygenic scoring. The project will also plan to make insights and tools widely available to the research community, including methods to calculate an individual’s risk of developing common diseases based on millions of variants in the genome.

Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through 2028 due to the high prevalence of abdominal aortic aneurysms (AAA) relative to thoracic abdominal aneurysms (TAA), according to a new report from GlobalData. The abdominal segment will reach an estimated $2.8 billion global value by 2028, while the overall global aortic stent graft market is expected to reach $4.5 billion in the same period. This represents a compound annual growth rate of 5.4 percent between 2018 and 2028.